Shenogen is focused on the discovery and development of first-in-class therapeutics for cancer treatment. After years of efforts, we have developed an impressive
- The “Oncotarget” paper published by Drs. Guo and Liu from Shenogen introduced SNG1153 recent MOA progress on lung cancer therapy
- Carcinogenesis: Singapore researchers reveal mechanism of icaritin suppressing prostate cancer
- Shenogen’s Charlie Wang and Qingcong Lin selected as Members of Beijing Foreign Talents Recruiting (Haiju) Program
- Shenogen’s Charlie Wang elected as member of
- Shenogen Announces a New Member to Scientific Advisory Board: Dr. Genhong Cheng
- Icaritin Enters Fast Track Review for NDA
Shenogen Pharma Group is a drug discovery and development company founded in 2006 based in Beijing, China that dedicated the development of first-in-class therapeutics for cancer treatment. We possess robust intellectual property rights around a novel membrane-bound estrogen receptor, ER-alpha 36, which is related to tumor metastasis...
product pipeline consisting of small molecule and antibody drugs. Our products are safe and efficient, specifically targeting a novel estrogen receptor ER-alpha 36...